• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Ovid pauses ph. 2 plans for ROCK2 inhibitor to mull rival`s data

    FIERCE BIOTECH

    Ovid Therapeutics Reports Business & Q3 2024 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics to Host Investor Event

    GLOBENEWSWIRE

    Ovid Therapeutics Presents Pre-Clinical Results On OV329

    GLOBENEWSWIRE

    Meg Alexander Becomes President And COO At Ovid Therapeutics

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ovid Halts Preclinical Work, IV Seizure Program After Soticlestat Phase 3

    FIERCE BIOTECH

    Ovid Therapeutics Reports Q2 2024 Results And Business Updates

    GLOBENEWSWIRE

    Ovid Therapeutics Appoints Dr Amanda Banks As Chief Development Officer

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at Upcoming August Investor Conferences

    GLOBENEWSWIRE

    Ovid Therapeutics Expands Scientific Advisory Board With New Appointments

    GLOBENEWSWIRE

    ENeuro Publishes Findings On OV329`s Anti-Convulsant Properties

    GLOBENEWSWIRE

    Ovid And Graviton Report OV888/GV101 Phase 1 Data For CCM

    GLOBENEWSWIRE

    Takeda`s seizure drug fails to meet main goal in late-stage studies

    REUTERS

    Ovid Reports On Takeda’s Phase 3 Topline Results For Soticlestat

    GLOBENEWSWIRE

    Ovid Therapeutics Reports Business Updates, Q1 2024 Results

    GLOBENEWSWIRE

    Ovid Therapeutics To Present At H.C. Wainwright BioConnect Conference

    GLOBENEWSWIRE

    Ovid to Present at the 23rd Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Marinus Comments on Patent Challenge by Ovid & Provides Update

    BUSINESSWIRE

    Ovid asks USPTO to review Marinus` patent around serious seizure condition

    ENDPTS

    Ovid Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at the Oppenheimer 34th Annual Conference

    GLOBENEWSWIRE

    Ovid to Present Five Abstracts at the 77th American Epilepsy Meeting (2023)

    GLOBENEWSWIRE

    Ovid Therapeutics Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement

    GLOBENEWSWIRE

    Ovid sells some royalty rights to Takeda-partnered seizure drug

    FIERCE BIOTECH

    Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

    GLOBENEWSWIRE

    Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

    GLOBENEWSWIRE

    Ovid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

    GLOBENEWSWIRE

    Ovid Therapeutics to Participate in Upcoming September Investor Conferences

    GLOBENEWSWIRE

    Ovid Therapeutics Reports Q2 2023 Financial Results and Corporate Updates

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

    GLOBENEWSWIRE

    Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints CSO

    GLOBENEWSWIRE

    Ovid Therapeutics Added to Russell 3000® Index

    GLOBENEWSWIRE

    Ovid Therapeutics Reports 1Q 2023 Financial Results and Corporate Updates

    GLOBENEWSWIRE

    Ovid snaps up Rock2 inhibitor from Sam Waksal-led Graviton

    FIERCE BIOTECH

    Ovid partners with Waksal startup to develop drugs for rare brain disorders

    BIOPHARMADIVE

    Ovid Announces Collaboration with Graviton Bioscience, ROCK2 Inhibitors

    GLOBENEWSWIRE

    Long-term Safety &Efficacy Findings from Soticlestat Open Label Extension Study

    GLOBENEWSWIRE

    Ovid to Present at the 22nd Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Ovid Reports Business Update, Fourth Quarter & Full Year 2022 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at 2nd Annual Needham Virtual Neuroscience Forum

    GLOBENEWSWIRE

    Studies Published Validate the Potential of Direct KCC2 Activation

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

    GLOBENEWSWIRE

    Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

    GLOBENEWSWIRE

    Ovid brings two Big Pharma vets on board as new CMO, head of epilepsy research

    ENDPTS

    Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

    GLOBENEWSWIRE

    Ovid Therapeutics to Present Data on Its Epilepsy Programs at AESAM(2022)

    GLOBENEWSWIRE

    Ovid Therapeutics Reports3Q 2022 Financial Results and Corporate Highlights

    GLOBENEWSWIRE

    Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Conference

    GLOBENEWSWIRE

    gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Acute Withdrawal

    GLOBENEWSWIRE

    Ovid turns to gene therapy startup to restock drug pipeline

    BIOPHARMADIVE

    Ovid Therapeutics Reports Second Quarter 2022 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics Presents Preclinical Data on OV329 at the EFP Conference

    GLOBENEWSWIRE

    Ovid Tx to Present at 21st Annual Needham Virtual Healthcare Conference

    GLOBENEWSWIRE

    Ovid cuts 20% of staff, refocuses on epilepsy

    FIERCEBIOTECH

    Ovid Tx Reports Business Update, Q4 and FY 2021 Financial Results

    GLOBENEWSWIRE

    Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

    GLOBENEWSWIRE

    Ovid pens deal to offload twice-failed former lead program

    BIOSPACE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.